Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 7 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 2 |
| Women s Health Therapeutics Market to 2018 - Introduction | 12 | 1 |
| Overview | 12 | 1 |
| Women s Health Therapeutics Market to 2018 - Market Overview | 13 | 7 |
| Introduction | 13 | 1 |
| Revenue Forecasts for the Women s Health Therapeutics Market | 14 | 1 |
| Revenues | 14 | 1 |
| Annual Cost of Therapy | 15 | 1 |
| Branded and Generic Market Share | 16 | 1 |
| Treatment Usage Patterns | 17 | 2 |
| Drivers and Barriers for the Women s Health Therapeutics Market | 19 | 1 |
| Drivers for the Women s Health Therapeutics Market | 19 | 1 |
| Introduction of First-in-Class Therapies with Better Safety and Efficacy | 19 | 1 |
| Increase in the Treatment Seeking Population Due to Increasing Awareness about Women s Health Disorders | 19 | 1 |
| Barriers for the Women s Health Therapeutics Market | 19 | 1 |
| Availability of Alternative Treatment Options Such as Yoga, Physiotherapy and Other Lifestyle Changes | 19 | 1 |
| Women s Health Therapeutics Market to 2018 - Geographical Landscape | 20 | 15 |
| The US | 20 | 1 |
| Revenue | 20 | 1 |
| Annual Cost of Therapy | 21 | 1 |
| Treatment Usage Pattern | 22 | 1 |
| Top Five Countries of Europe | 23 | 1 |
| Revenue | 23 | 2 |
| Annual Cost of Therapy | 25 | 1 |
| Treatment Usage Pattern | 26 | 1 |
| Japan | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Therapy | 28 | 1 |
| Treatment Usage Pattern | 29 | 1 |
| Women s Health Therapeutics Market, Australia - Overview | 30 | 1 |
| Epidemiology | 30 | 1 |
| Clinical Trials | 30 | 1 |
| Drivers and Restraints | 31 | 1 |
| Women s Health Therapeutics Market, India - Overview | 31 | 1 |
| Epidemiology | 31 | 1 |
| Clinical Trials | 32 | 1 |
| Drivers and Restraints | 32 | 1 |
| Women s Health Therapeutics Market, China - Overview | 33 | 1 |
| Epidemiology | 33 | 1 |
| Clinical Trials | 33 | 1 |
| Drivers and Restraints | 34 | 1 |
| Women s Health Therapeutics Market to 2018 - Therapeutic Landscape | 35 | 62 |
| Menopause | 35 | 1 |
| Introduction | 35 | 1 |
| Hormone Therapy and the Women s Health Initiative Study | 35 | 1 |
| Revenues | 36 | 1 |
| Geographical Segmentation | 37 | 1 |
| Branded and Generic Market Share | 38 | 1 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Major Marketed Products in the Menopause Therapeutics Market | 41 | 1 |
| Premarin (conjugated estrogens) | 41 | 1 |
| Vagifem (estradiol vaginal tablets) | 42 | 1 |
| Femring (estradiol acetate vaginal ring) | 43 | 1 |
| Prempro (conjugated estrogens/medroxyprogesterone acetate tablets) | 43 | 1 |
| Drivers for the Menopause Therapeutics Market | 44 | 1 |
| Ageing Population | 44 | 1 |
| Barriers for the Menopause Therapeutics Market | 45 | 1 |
| Low Prescription Rate | 45 | 1 |
| Availability of Alternative Options | 45 | 1 |
| Postmenopausal Osteoporosis | 45 | 1 |
| Introduction | 45 | 1 |
| Revenues | 46 | 1 |
| Geographical Segmentation | 47 | 1 |
| Branded versus Generic Market Share | 48 | 1 |
| Annual Cost of Therapy | 49 | 1 |
| Treatment Usage Patterns | 50 | 2 |
| Treatment Flow Algorithm | 52 | 1 |
| Major Marketed Drugs in the Postmenopausal Osteoporosis Market | 53 | 1 |
| Fosamax (alendronate sodium) | 54 | 1 |
| Actonel (risedronate sodium) | 55 | 1 |
| Evista (raloxifene hydrochloride) | 56 | 1 |
| Boniva (ibandronate sodium) | 57 | 2 |
| Forteo (teriparatide [rDNA origin]) injection | 59 | 1 |
| Drivers for the Postmenopausal Osteoporosis Market | 60 | 1 |
| Increase in Awareness | 60 | 1 |
| Increase in the Prevalence Population | 60 | 1 |
| Barriers for the Postmenopausal Osteoporosis Market | 61 | 1 |
| Poor Diagnosis of the Disease | 61 | 1 |
| Increase in the Use of Generics | 61 | 1 |
| Endometriosis | 61 | 1 |
| Introduction | 61 | 1 |
| Revenues | 62 | 1 |
| Geographical Segmentation | 63 | 1 |
| Branded and Generic Market Share | 64 | 1 |
| Annual Cost of Therapy | 65 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Treatment Flow Algorithm | 67 | 1 |
| Major Marketed Drugs for Endometriosis | 68 | 1 |
| Lupron Depot | 68 | 1 |
| Synarel | 69 | 1 |
| Zoladex | 70 | 1 |
| Drivers for the Endometriosis Therapeutics Market | 71 | 1 |
| Increasing Awareness Among Physicians and Patients | 71 | 1 |
| Increase in Funding for Endometriosis Research | 71 | 1 |
| Barriers for the Endometriosis Therapeutics Market | 72 | 1 |
| Low Diagnosis Rate | 72 | 1 |
| Infertility | 72 | 1 |
| Introduction | 72 | 1 |
| Revenues | 73 | 1 |
| Geographical Segmentation | 74 | 1 |
| Branded and Generic Market Share | 75 | 1 |
| Annual Cost of Therapy | 76 | 1 |
| Treatment Usage Patterns | 77 | 1 |
| Treatment Flow Algorithm | 78 | 1 |
| Major Marketed Drugs in the Infertility Therapeutics Market | 79 | 1 |
| Ovidrel (choriogonadotropin alfa) | 79 | 1 |
| Gonal-f (follitropin alfa) | 80 | 2 |
| Bravelle (urofollitropin) | 82 | 2 |
| Drivers for the Infertility Therapeutics Market | 84 | 1 |
| Increase in Patient Acceptance | 85 | 1 |
| Barriers for the Infertility Therapeutics Market | 85 | 1 |
| Increase in Generic Competition | 85 | 1 |
| Female Contraceptives | 85 | 1 |
| Introduction | 85 | 2 |
| Revenues | 87 | 1 |
| Segmentation by Type | 88 | 1 |
| Geographical Segmentation | 89 | 1 |
| Share of Prescription and OTC Contraceptives | 90 | 1 |
| Annual Cost of Usage | 91 | 1 |
| Treatment Usage Patterns | 92 | 1 |
| Major Marketed Products in the Female Contraceptives Market | 93 | 1 |
| Yasmin | 94 | 1 |
| Mirena | 94 | 1 |
| Nuvaring | 94 | 1 |
| Drivers for the Female Contraceptives Market | 95 | 1 |
| Increase in Awareness Levels Concerning the Use of Contraceptives | 95 | 1 |
| Increase in Government Initiatives to Provide Publicly Funded Contraceptives | 95 | 1 |
| Changes in Beliefs Regarding the Use of Contraceptives | 95 | 1 |
| Barriers for the Female Contraceptives Market | 96 | 1 |
| Side Effects of Contraceptives | 96 | 1 |
| Patent Expiry of Contraceptives | 96 | 1 |
| Women s Health Therapeutics Market to 2018 - Pipeline Analysis | 97 | 14 |
| Overview | 97 | 2 |
| Research and Development Pipeline - Menopause | 99 | 1 |
| Overview | 99 | 1 |
| Research and Development Pipeline - Postmenopausal Osteoporosis | 99 | 1 |
| Overview | 99 | 1 |
| Research and Development Pipeline - Endometriosis | 100 | 1 |
| Overview | 100 | 1 |
| Research and Development Pipeline - Infertility | 100 | 1 |
| Overview | 100 | 1 |
| Research and Development Pipeline - Female Sexual Dysfunction | 101 | 1 |
| Overview | 101 | 1 |
| Research and Development Pipeline - Contraceptives | 102 | 1 |
| Overview | 102 | 1 |
| Profiles of Promising Drugs in the Women s Health Therapeutics Market | 103 | 1 |
| Menerba | 103 | 1 |
| Class of Drug | 103 | 1 |
| Indication | 103 | 1 |
| Clinical Trials | 103 | 1 |
| Expected Approval Timeline | 104 | 1 |
| Odanacatib | 104 | 1 |
| Class of Drug | 104 | 1 |
| Indication | 104 | 1 |
| Clinical Trials | 104 | 1 |
| Expected Approval Timeline | 104 | 1 |
| Elagolix | 105 | 1 |
| Class of Drug | 105 | 1 |
| Indication | 105 | 1 |
| Clinical Trials | 105 | 1 |
| Expected Approval Time | 105 | 1 |
| Deals | 105 | 1 |
| Libigel | 106 | 1 |
| Class of Drug | 106 | 1 |
| Indication | 106 | 1 |
| Clinical Trials | 106 | 1 |
| Expected Approval Time | 106 | 1 |
| Deals | 107 | 1 |
| Femprox | 107 | 1 |
| Class of Drug | 107 | 1 |
| Indication | 107 | 1 |
| Clinical Trials | 107 | 1 |
| Expected Approval Time | 107 | 1 |
| MK 8962 | 108 | 1 |
| Class of Drug | 108 | 1 |
| Indication | 108 | 1 |
| Clinical Trials | 108 | 1 |
| Expected Approval Time | 108 | 1 |
| Zoely | 109 | 1 |
| Class of Drug | 109 | 1 |
| Indication | 109 | 1 |
| Clinical Trials | 109 | 1 |
| Expected Approval Time | 109 | 1 |
| Deals | 109 | 1 |
| AMG 785 | 110 | 1 |
| Class of Drug | 110 | 1 |
| Indication | 110 | 1 |
| Clinical Trials | 110 | 1 |
| Expected Approval Timeline | 110 | 1 |
| Deals | 110 | 1 |
| Women s Health Therapeutics Market to 2018 - Competitive Landscape | 111 | 9 |
| Market Share Analysis: Women s Health Therapeutics Market | 111 | 1 |
| Competitive Profiling | 112 | 1 |
| Warner Chilcott | 112 | 1 |
| Overview | 112 | 1 |
| Major Marketed Products | 112 | 1 |
| SWOT | 113 | 1 |
| Pfizer | 113 | 1 |
| Overview | 113 | 1 |
| Major Marketed Products | 114 | 1 |
| SWOT | 114 | 1 |
| Eli-Lilly | 115 | 1 |
| Overview | 115 | 1 |
| Major Marketed Products | 115 | 1 |
| SWOT | 115 | 1 |
| Merck | 116 | 1 |
| Overview | 116 | 1 |
| Major Marketed Products | 116 | 1 |
| SWOT | 117 | 1 |
| Roche | 118 | 1 |
| Overview | 118 | 1 |
| Major Marketed Products | 118 | 1 |
| SWOT | 118 | 1 |
| Bayer | 119 | 1 |
| Overview | 119 | 1 |
| Major Marketed Products | 119 | 1 |
| SWOT | 119 | 1 |
| Women s Health Therapeutics Market to 2018 - Strategic Consolidations | 120 | 10 |
| Overview | 120 | 1 |
| Deals by Year | 120 | 1 |
| Deals by Type | 121 | 1 |
| Deals by Value | 121 | 1 |
| Mergers and Acquisitions | 122 | 2 |
| Major M&A Deals | 124 | 1 |
| Ferring Pharma Acquires Cytokine PharmaSciences and Controlled Therapeutics | 124 | 1 |
| Teva Pharma Industries Acquires THERAMEX from Merck Serono | 124 | 1 |
| Licensing Agreements | 125 | 2 |
| Major Licensing Agreements | 127 | 1 |
| Bayer Schering Enters into Licensing Agreement with EndoCeutics | 127 | 1 |
| Osteologix Enters into Licensing Agreement with Servier Research | 127 | 1 |
| Partnerships | 128 | 1 |
| Major Partnership Deals | 129 | 1 |
| Abbott Labs Enters into Co-Development Agreement with Neurocrine Biosciences | 129 | 1 |
| Unigene Labs Enters into Co-Development Agreement with GlaxoSmithKline | 129 | 1 |
| Women s Health Therapeutics Market to 2018 - Appendix | 130 | 8 |
| Abbreviations | 130 | 1 |
| Market Definitions | 131 | 1 |
| Bibliography | 131 | 1 |
| Research Methodology | 132 | 3 |
| Coverage | 133 | 1 |
| Secondary Research | 133 | 1 |
| Primary Research | 133 | 1 |
| Expert Panel Validation | 134 | 1 |
| Section-wise Research Methodology | 134 | 1 |
| Therapeutic Landscape | 134 | 3 |
| Epidemiology-based Forecasting | 135 | 1 |
| Market Size by Geography | 136 | 1 |